Insider Selling: Billiontoone (NASDAQ:BLLN) CEO Sells $516,184.50 in Stock

Billiontoone, Inc. (NASDAQ:BLLN) CEO Oguzhan Atay sold 5,150 shares of Billiontoone stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $100.23, for a total value of $516,184.50. Following the transaction, the chief executive officer owned 3,183 shares of the company’s stock, valued at approximately $319,032.09. This represents a 61.80% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oguzhan Atay also recently made the following trade(s):

• On Wednesday, October 14th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total transaction of $261,366.00.
• On Wednesday, October 14th, Oguzhan Atay sold 3,183 shares of Billiontoone stock. The stock was sold at an average price of $98.34, for a total value of $313,016.22.
• On Monday, October 12th, Oguzhan Atay sold 2,667 shares of Billiontoone stock. The stock was sold at an average price of $97.61, for a total value of $260,325.87.
• On Monday, October 12th, Oguzhan Atay sold 16,667 shares of Billiontoone stock. The stock was sold at an average price of $93.79, for a total transaction of $1,563,197.93.
• On Monday, September 28th, Oguzhan Atay sold 2,666 shares of Billiontoone stock. The shares were sold at an average price of $120.64, for a total transaction of $321,626.24.
• On Monday, September 28th, Oguzhan Atay sold 8,333 shares of Billiontoone stock. The stock was sold at an average price of $120.64, for a total transaction of $1,005,293.12.
• On Monday, September 14th, Oguzhan Atay sold 5,332 shares of Billiontoone stock. The stock was sold at an average price of $98.00, for a total transaction of $522,536.00.
• On Monday, September 14th, Oguzhan Atay sold 24,999 shares of Billiontoone stock. The stock was sold at an average price of $100.32, for a total transaction of $2,507,899.68.
• On Monday, August 3rd, Oguzhan Atay sold 12,500 shares of Billiontoone stock. The shares were sold at an average price of $137.37, for a total transaction of $1,717,125.00.
• On Monday, August 3rd, Oguzhan Atay sold 32,500 shares of Billiontoone stock. The shares were sold at an average price of $136.95, for a total transaction of $4,450,875.00.

Billiontoone Price Performance

BLLN stock traded down $4.61 during trading on Friday, hitting $98.12. The stock had a trading volume of 605,635 shares, compared to its average volume of 654,157. The company has a debt-to-equity ratio of 0.17, a current ratio of 11.69 and a quick ratio of 11.31. Billiontoone, Inc. has a twelve month low of $61.96 and a twelve month high of $150.44. The stock has a market capitalization of $4.63 billion and a P/E ratio of 146.76. The company’s 50-day moving average price is $100.99 and its two-hundred day moving average price is $101.58.

Billiontoone (NASDAQ:BLLN) last posted its quarterly earnings data on Wednesday, August 5th. The company reported $0.15 EPS for the quarter, hitting the consensus estimate of $0.15. Billiontoone had a return on equity of 9.96% and a net margin of 8.04%. The company had revenue of $109.45 million during the quarter. As a group, research analysts predict that Billiontoone, Inc. will post 0.80 EPS for the current fiscal year.

Wall Street Analyst Weigh In

BLLN has been the topic of a number of research reports. Wall Street Zen lowered Billiontoone from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Guggenheim upped their target price on shares of Billiontoone from $125.00 to $128.00 and gave the stock a “buy” rating in a report on Thursday, October 1st. Weiss Ratings cut shares of Billiontoone from a “sell (d+)” rating to a “sell (d)” rating in a research report on Thursday, October 8th. Zacks Research upgraded shares of Billiontoone from a “strong sell” rating to a “hold” rating in a research report on Friday, October 2nd. Finally, Canaccord Genuity Group began coverage on shares of Billiontoone in a research note on Wednesday, September 2nd. They issued a “buy” rating and a $120.00 price target on the stock. Seven analysts have rated the stock with a Buy rating, three have assigned a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, Billiontoone presently has a consensus rating of “Moderate Buy” and an average target price of $126.25.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently made changes to their positions in the stock. Integrated Wealth Concepts LLC purchased a new stake in shares of Billiontoone in the second quarter valued at approximately $29,000. Family Legacy Financial Solutions LLC acquired a new stake in shares of Billiontoone in the third quarter valued at approximately $53,000. MCF Advisors LLC lifted its position in Billiontoone by 330.8% during the second quarter. MCF Advisors LLC now owns 448 shares of the company’s stock worth $54,000 after buying an additional 344 shares in the last quarter. Toth Financial Advisory Corp grew its holdings in Billiontoone by 60.0% in the 3rd quarter. Toth Financial Advisory Corp now owns 800 shares of the company’s stock valued at $85,000 after buying an additional 300 shares in the last quarter. Finally, Caitong International Asset Management Co. Ltd purchased a new stake in Billiontoone in the 4th quarter valued at $230,000.

About Billiontoone

BillionToOne, Inc (NASDAQ:BLLN) is a molecular diagnostics company that develops blood-based genetic tests designed to provide more information from small amounts of cell-free DNA. The company’s platform uses proprietary molecular counting technology to improve the sensitivity and accuracy of diagnostic testing.

BillionToOne’s primary business is reproductive health testing. Its UNITY portfolio is designed to support prenatal screening, including testing for chromosomal conditions and single-gene disorders, and is intended to provide physicians and expectant parents with information from a maternal blood sample.